Genetic Stability Testing Using NGS and MAM: Optimizing CHO Cell Line Development
September 11, 2025
Valentina Armiento
The pharmaceutical market is undergoing rapid expansion in biologics, including vaccines, monoclonal antibodies (mAbs), bispecific and multi-specific antibodies, and antibody-drug conjugates (ADCs). Chinese Hamster Ovary (CHO) cell lines are used to produce approximately 70% of all biologics1 due to their high productivity and ability to thrive in suspension cultures. As a result, characterizing and confirming the genetic stability of these cell lines is essential and requires rigorous testing methods that comply with strict regulatory standards.
This article explores best practices for conducting genetic stability testing in CHO cell line development and highlights the advantages of next-generation sequencing (NGS) and the multi-attribute method (MAM) in ensuring product consistency, safety, and long-term reliability.
What is Genetic Stability Testing?
Genetic stability testing is the process of verifying that a cell line retains its genetic composition over time, without accumulating mutations or structural changes that could impact product quality. In biopharmaceutical manufacturing, this ensures that CHO cell lines consistently produce biologics with the intended potency, safety, and efficacy.
As a foundational element of regulatory compliance, genetic stability testing supports long-term product reliability and helps manufacturers meet stringent quality standards throughout development and production.
Traditional Method vs. Next-Generation Sequencing (NGS) for Genetic Stability Testing
Traditional methods for testing genetic stability, such as PCR, Sanger sequencing, karyotyping, fluorescence in situ hybridization (FISH), and Southern blot analysis, are time-consuming, labor- and resource-intensive, and costly. In many cases, these techniques provide only qualitative assessments that are open to subjective interpretation. As a result, conclusive testing typically requires multiple distinct assays to evaluate genomic stability.
NGS stands out as the most accurate and comprehensive method for genetic stability testing available today. From host cell line development to the characterization of the master cell bank, NGS provides molecular insights at the sequence level, enabling continuous tracking of genetic stability throughout the entire process. It facilitates comprehensive sequencing of the entire genome, identifying even the smallest genetic variations that could impact biologics production. The precision of NGS ensures early detection of genetic drift or mutations in CHO cell lines, allowing for timely interventions.
Key Benefits of Using NGS for Genetic Stability Testing in CHO Cell Lines
NGS offers several distinct advantages over traditional methods:
- Comprehensive genomic coverage: NGS provides a base-by-base view of the entire genome, enabling precise detection of even minor genetic changes.
- Early detection of genetic drift and mutations: By identifying variations at the molecular level, NGS allows for proactive measures to maintain cell line integrity and prevent downstream production issues.
- Improved cost-efficiency and time savings: While initial setup may be more advanced, NGS reduces the need for multiple assays and manual interpretation, streamlining testing workflows and lowering long-term costs.
- Scalability and reproducibility: NGS workflows can be standardized and scaled across projects, ensuring consistent results and regulatory compliance.
Integrating Multi-Attribute Method (MAM) with NGS for Enhanced Testing
Originally developed for mass spectrometry, the Multi-Attribute Method (MAM) is now being integrated with other technologies, including NGS. MAM is designed to simultaneously detect, analyze, and monitor multiple Critical Quality Attributes (CQAs) within a single sample. The emerging trend of combining MAM with NGS streamlines the testing process and provides a comprehensive view of both the genetic stability and functional attributes of CHO producer lines.
Implementing MAM enables deeper insights into CHO cell lines during production and supports consistent monitoring of both genetic and phenotypic stability. It can replace traditional methods for tracking genetic changes and detect variations that may be missed by conventional techniques. Once NGS instrumentation, wet laboratory protocols, and analytical workflows are established in-house, the NGS-MAM approach can significantly reduce resource requirements, cut timelines by up to fivefold, and lower costs, while still delivering high-quality results and robust decision support.
The Challenges of In-House NGS-MAM Implementation
Establishing NGS-MAM for in-house CHO cell line development and stability testing presents several key challenges. These include building a robust bioinformatics and data analysis infrastructure, and assembling a team with deep expertise in both NGS and complex data analysis. Integrating NGS-MAM into existing workflows and scaling it across operations also requires careful coordination with other laboratory systems.
Moreover, the entire process, from sample preparation to data analysis and reporting, must be validated to meet regulatory standards. Despite these challenges, the combined use of NGS and MAM remains the most efficient and accurate approach for genetic stability testing in CHO cell lines. Its benefits, including enhanced precision and accuracy, increased efficiency, and long-term cost savings, make it a valuable investment for biopharmaceutical companies committed to quality and innovation.
Optimizing Genetic Stability Testing for CHO Cell Lines with Genedata Selector
Genedata Selector® offers a unique solution to address the challenges of implementing NGS-MAM, making setup and maintenance significantly easier and more cost-efficient. It automates the simultaneous analysis of multiple NGS assays and provides a validated platform that meets regulatory requirements. This automation not only simplifies the testing process but also ensures scalability, reproducibility, and operational efficiency. Once established, Genedata Selector streamlines NGS-MAM workflows, making them more reliable and consistent. It also frees up bioinformaticians to focus on higher-value projects.
To fully realize the potential of MAM in NGS-based genetic stability testing, seamless integration and interpretation of complex data is essential. Genedata Selector delivers an end-to-end solution for data processing and analysis using whole genome sequencing (WGS) with NGS. The platform includes a comprehensive suite of tools for developing and analyzing various cell line characterization assays within a single, integrated environment. It supports NGS sample tracking, manages diverse bioinformatics workflows, analyzes results, and automatically generates standardized reports for regulatory submissions. Additionally, it maintains traceability between raw and processed NGS data, tracks assay parameters, and manages reference libraries. By using Genedata Selector, cell line development (CLD) teams gain a holistic view of the CHO clone genome, enhancing both the accuracy and precision of genetic stability assessments.
Advantages of Genedata Selector
Regulatory Compliance and Genetic Stability Testing
To meet global regulatory standards, including those set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), advanced technologies such as NGS are essential in CHO cell line development. The ICH Q5A(R2) guideline emphasizes the importance of ensuring genetic stability and viral safety in production cell lines. NGS enables comprehensive analysis of the gene of interest (GOI) and its flanking regions, offering detailed insights into structural variants and potential recombination events. This advanced approach addresses the limitations of traditional methods and ensures genetic integrity in manufacturing cell lines through a single, integrated assay.
The Most Efficient Way to Ensure Genetic Stability of CHO Cells
Genedata Selector leverages cutting-edge in NGS and bioinformatics capabilities to simplify and enhance genetic stability testing throughout the CLD process, from clone selection to bioprocess development and master cell bank (MCB) characterization. Using WGS, the end-to-end platform provides a high-resolution, base-by-base view of the entire CHO genome, including exogenous genes and vector elements. This eliminates the need for primer design and reduces subjective interpretation, enabling more accurate and comprehensive analysis.
The platform automates the analysis and visualization of genetic elements, generating detailed reports that meet regulatory standards. It confirms the nucleotide sequence of the GOI and flanking regions, detects single nucleotide polymorphisms (SNPs), insertions, and deletions, and eliminates primer bias to ensure complete sequencing of inserted genes. Genedata Selector also determines gene copy number by comparing sequencing coverage of inserted regions to reference genes in the CHO genome. Furthermore, it identifies precise integration sites, including chromosome number and coordinates, and assesses the structural integrity of the vector expression cassette by analyzing chimeric reads and identifying vector-vector junctions. This approach provides validated insights into structural variants and potential recombination events, ensuring precision, accuracy, linearity, and range for reliable results.
Validating Multiple NGS Assays
Genedata Selector provides a validated platform for a wide range of assays, offering comprehensive support for genetic stability testing. A dedicated Quality Assurance (QA) team — built on years of close collaboration with biopharmaceutical partners — ensures that Genedata Selector consistently meets the highest standards of quality and reliability. It also supports additional validation needs for novel workflows, ensuring flexibility as testing requirements evolve.
This enables companies to focus on their core objectives without the burden of developing and maintaining a custom NGS infrastructure or undergoing lengthy validation processes for individual assays. By leveraging Genedata Selector, organizations can adopt state-of-the-art technology for genetic stability testing while streamlining operations and accelerating timelines.
Summary
Genedata Selector represents a major advancement in genetic stability testing for CHO cell lines and Adventitious Agent Detection (AAD), simplifying and streamlining the in-house implementation of NGS-MAM. The cutting-edge platform automates complex workflows, enhances scalability, and delivers comprehensive insights throughout the testing process.
Its ability to validate multiple assays simultaneously enables faster, more reliable, and more robust testing while ensuring compliance with regulatory standards. Looking ahead, NGS-MAM is expected to become the preferred method for genetic stability and AAD testing, offering a more efficient and dependable approach to meet evolving regulatory requirements.
References
- Tihanyi, B.; Nyitray, L. Recent Advances in CHO Cell Line Development for Recombinant Protein Production. Drug Discovery Today: Technol.2020, 38, 25–34. doi.org/10.1016/j.ddtec.2021.02.003.